We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Potential Shortcoming of Antibiotic Lab Tests Determined

By LabMedica International staff writers
Posted on 18 Jul 2018
As multidrug-resistant organisms continue to emerge, specific tests, called antibiotic susceptibility assays, are increasingly critical. More...
Clinicians depend on reliable results when choosing the right drug to treat patients.

To determine which antibiotics reliably treat which bacterial infections, diagnostic laboratories that focus on clinical microbiology test pathogens isolated from patients for antibiotic sensitivity. However, a recent study reveals that one aspect of these tests may fall short and not be stringent enough.

Microbiologists at the Beth Israel Deaconess Medical Center (Boston MA, USA) and their colleagues examined pathogens cited by the US Centers for Disease Control and Prevention (Atlanta GA, USA) and the World Health Organization (Geneva, Switzerland) as urgent and concerning drug resistance threats.

To obtain consistently reliable results, scientists conducting antibiotic susceptibility assays follow national guidelines with standardized methods, including the use of a specific number of organisms, or "inoculum" that is added to each assay. There is a target inoculum, and then a range of an allowable inoculum, or acceptable upper and lower bounds around the target inoculum.

The team found that the susceptibility determination against two broad spectrum drugs, meropenem and cefepime, were dramatically affected by inoculum differences within the allowable range of inoculum. Although they have no idea about how often clinical laboratories deviate even beyond the allowable range, they expect this happens with some frequency and would further skew results. The findings indicate that clinical microbiology laboratories must hit the target inoculum as accurately as possible to obtain reliable testing results for multidrug-resistant pathogens.

James Kirby, MD, the Director of the Clinical Microbiology Laboratory and senior co-author, said, “Our question was whether this wiggle room impacts results. Our findings were clear: inoculum matters.” The study was published on May 21, 2018, in the journal Antimicrobial Agents and Chemotherapy.

Related Links:
Beth Israel Deaconess Medical Center
US Centers for Disease Control and Prevention
World Health Organization


New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Online QC Software
Acusera 24•7
New
Automated Urinalysis Solution
UN-9000
New
Multi-Chamber Washer-Disinfector
WD 390
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Roche’s CE-Marked Elecsys pTau217 blood test is a single‑assay blood test measures phosphorylated tau 217, an indicator of amyloid pathology and a hallmark of Alzheimer’s disease (image credit: Shutterstock)

Blood-Based Alzheimer’s Test Gains CE Mark for Amyloid Pathology Detection

Alzheimer’s disease is the most common cause of dementia, yet confirmatory testing remains invasive and hard to access. Diagnosis currently takes an average of 3.5 years, and about 75% of people with dementia... Read more

Molecular Diagnostics

view channel
Image: Clarifying tumor microenvironment features and cancer-cell programs linked to treatment response could provide earlier insight into triple-negative breast cancer therapy (image credit: Shutterstock)

Gene Panel Shows Promise for Predicting Chemotherapy Response in TNBC

Triple-negative breast cancer (TNBC) is an aggressive subtype commonly treated with chemotherapy, yet outcomes vary widely among patients. Understanding the tumor features that drive this variability remains... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.